Genetically engineered animals in drug discovery and development: A maturing resource for toxicologic research

Basic and Clinical Pharmacology and Toxicology

Volumn 95, Issue 4, 2004, Pages 154-161

  Bolon, Brad ^a  

^a GEMpath Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; BIOASSAY; CARCINOGENESIS; COMPARATIVE TOXICOLOGY; DATA ANALYSIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ENGINEERING; GENOTOXICITY; IN VIVO STUDY; KNOCKOUT MOUSE; LATENT PERIOD; MOLECULAR MECHANICS; MOUSE; MOUSE STRAIN; MUTAGENICITY; NONHUMAN; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; TOXICOLOGY; TRANSGENIC MOUSE; XENOBIOTIC METABOLISM;

ANIMALIA; MUS MUSCULUS;

EID: 8144221194     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto950402.x     Document Type: Short Survey

References (67)

1. Bolon, B., E. Galbreath, L. Sargent & J. Weiss: Genetic engineering and molecular technology. In: The laboratory rat. Ed.: G. Krinke. Academic Press, London, 2000, pp. 603-634.
2. Bolon, B. & E. J. Galbreath: Use of genetically engineered mice in drug discovery and development: Wielding Occam's razor to prune the product portfolio. Int. J. Toxicol. 2002, 21, 55-64.
3. Bolon, B., S. Jing, F. Asuncion, S. Scully, M. Pisegna, G. Van, Z. Hu, Y. B. Yu, H. Min, K. Wild, R. D. Rosenfeld, J. Tarpley, J. Carnahan, D. Duryea, D. Hill, S. Kaufman, X.-Q. Yan, T. Juan, K. Christensen, J. McCabe & W. S. Simonet: The candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing nerve dysfunction. Toxicol. Pathol. 2004, 32, 275-294.
4. Bolon, B., V. Shalhoub, P. J. Kostenuik, G. Campagnuolo, S. Morony, W. J. Boyle, D. Zack & U. Feige: Osteoprotegerin (OPG): an endogenous anti-osteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum. 2002, 46, 3121-3135.
5. Campbell, I. L., A. K. Stalder, Y. Akwa, A. Pagenstecher & V. C. Asensio: Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation 1998, 5, 126-135.
6. Charreau, B., L. Tesson, J. P. Soulillou, C. Pourcel & I. Anegon: Transgenesis in rats: technical aspects and models. Transgenic Res. 1996, 5, 223-234.
7. Contrera, J. F. & J. J. DeGeorge: In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Env. Health Perspect. 1998, 106, 71-80.
8. Cordaro, C. J.: Transgenic mice as future tools in risk assessment. Risk Analysis 1989, 9, 157-168.
9. Cosentino, L. & J. A. Heddle: Differential mutation of transgenic and endogenous loci in vivo. Mut. Res. 2000, 454, 1-10.
10. Deubel, W., I. Bassukas, W. Schlereth, R. Lorenz & K. Hempel: Age dependent selection against HPRT-deficient T lymphocytes in the HPRT+/- heterozygous mouse. Mut. Res. 1996, 351, 67-77.
11. Doetschman, T.: Interpretation of phenotype in genetically engineered mice. Lab. Animal Sci. 1999, 49, 137-143.
12. Eastin, W. C., J. H. Mennear, R. W. Tennant, R. E. Stoll, D. G. Branstetter, J. R. Bucher, B. McCullough, R. L. Binder, J. W. Spalding & J. F. Mahler: Tg.Ac genetically altered mouse: Assay working group overview of available data. Toxicol. Pathol. 2001, 29 (Suppl.), 60-80.
13. French, J., R. D. Storer & L. A. Donehower: The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol. Pathol. 2001, 29 (Suppl.), 24-29.
14. Friedberg, E. C., L. B. Meira & D. L. Cheo: Database of mouse strains carrying targeted mutations in genes affecting cellular responses to DNA damage. Version 2. Mut. Res. 1998, 407, 217-226.
15. Gingrich, J. A. & R. Hen: The broken mouse: the role of development, plasticity and environment in the interpretation of phenotypic changes in knockout mice. Curr. Opin. Neurobiol. 2000, 10, 146-152.
16. Goelz, M. F., J. Mahler, J. Harry, P. Myers, J. Clark, J. E. Thigpen & D. B. Forsythe: Neuropathologic findings associated with seizures in FVB mice. Lab. Animal Sci. 1998, 48, 34-37.
17. Goldsworthy, T. L., L. Recio, K. Brown, L. A. Donehower, J. C. Mirsalis, R. W. Tennant & I. F. H. Purchase: Transgenic animals in toxicology. Fundam. Appl. Toxicol. 1994, 22, 8-19.
18. Gonzalez, F. J.: The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol. Lett. 2001, 120, 199-208.
19. Gonzalez, F. J., P. Fernandez-Salguero & J. M. Ward: The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. J. Toxicol. Sci. 1996, 21, 273-277.
20. Gorelick, N. J., J. A. O'Kelly, V. E. Walker, J. G. DeBoer & B. W. Glickman: Validation issues for the use of transgenic mouse mutation assays in risk assessment. Toxicol. Pathol. 1995, 23, 823-824.
21. Gulezian, D., D. Jacobson-Kram, C. B. McCullough, H. Olson, L. Redo, D. Robinson, R. Storer, R. Tennant, J. M. Ward & D. A. Neumann: Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol. Pathol. 2000, 28, 482-499.
22. Haines, D. C., S. Chattopadhyay & J. M. Ward: Pathology of aging B6;129 mice. Toxicol. Pathol. 2001, 29, 653-661.
23. Korach, K. S., J. F. Couse, S. W. Curtis, T. F. Washburn, J. Lindzey, K. S. Kimbro, E. M. Eddy, S. Migliaccio, S. M. Snedeker, D. B. Lubahn, D. W. Schomberg & E. P. Smith: Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Progr. Harm. Res. 1996, 51, 159-186 [discussion, 186-188].
24. Lee, S. S., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez Salgeuro, H. Westphal & F. J. Gonzalez: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995, 15, 3102-3022.
25. -/-) null mutant mice develop normally but show deficient drug metabolism. Proc. Nat. Acad. Sci. USA 1996, 93, 1671-1676.
26. Liggitt, H. D. & G. M. Reddington: Transgenic animals in the evaluation of compound efficacy and toxicity: will they be as useful as they are novel? Xenobiotica 1992, 22, 1043-1054.
27. Linder, C. C.: The influence of genetic background on spontaneous and genetically engineered mouse models of complex diseases. Lab. Animal. 2001, 30, 34-39.
28. Livy, D. J. & D. Wahlsten: Tests of genetic allelism between four inbred mouse strains with absent corpus callosum. J. Heredity 1991, 82, 459-464.
29. Luo, Y., B. Bolon, M. A. Damore, D. Fitzpatrick, H. T. Liu, J. H. Zhang, Q. Yan, R. Vassar & M. Citron: BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol. Disease 2003, 14, 81-88.
30. Luo, Y., B. Bolon, S. Kahn, B. D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.-C. Louis, Q. Yan, W. G. Richards, M. Citron & R. Vassar: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nature Neurosci. 2001, 4, 213-232.
31. Mahler, J. F., W. Stokes, P. C. Mann, M. Takaoka & R. R. Maronpot: Spontaneous lesions in aging FVB/N mice. Toxicol. Pathol. 1996, 24, 710-716.
32. Maronpot, R. R.: The use of genetically modified animals in carcinogenicity bioassays. Toxicol. Pathol. 2000, 28, 450-453.
33. Mirsalis, J. C., J. A. Monforte & R. A. Winegar: Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicol. 1994, 24, 255-280.
34. Nebert, D. W., T. P. Dalton, G. W. Stuart & M. J. Carvan 3rd: "Gene-swap knock-in" cassette in mice to study allelic differences in human genes. Ann. NY Acad. Sci. 2000, 919, 148-170.
35. Nebert, D. W. & J. J. Duffy: How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem. Pharmacol. 1997, 53, 249-254.
36. Pich, E. M. & M. P. Epping-Jordan: Transgenic mice in drug dependence research. Ann. Med. 1998, 30, 390-396.
37. Pineau, T., P. Fernandez Salgeuro, S. S. T. Lee, T. McPhail, J. M. Ward & F. J. Gonzalez: Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 CYP1A2. Proc. Nat. Acad. Sci. USA 1995, 92, 5134-5138.
38. Piwnica-Worms, D. & M. Marmion: Characterization of drug specificity by pharmacokinetic analysis in gene knockout mice. J. Clin. Pharmacol. 1999, Suppl., 30S-33S.
39. Provost, G. S., P. L. Kretz, R. T. Hamner, C. D. Matthews, B. J. Rogers, K. S. Lundberg, M. J. Dycaico & J. M. Short: Transgenic systems for in vivo mutation analysis. Mut. Res. 1993, 288, 133-149.
40. Rudolph, U. & H. Moehler: Genetically modified animals in pharmacological research: future trends. Eur. J. Pharmacol. 1999, 375, 327-337.
41. Ryffel, B.: Impact of knockout mice in toxicology. Crit. Rev. Toxicol. 1997, 27, 135-154.
42. Schwenk, F., R. Kühn, P. O. Angrand, K. Rajewsky & A. F. Stewart: Temporally and spatially regulated somatic mutagenesis in mice. Nucleic Acids Res. 1998, 26, 1427-1432.
43. Sharp, J. J., L. E. Mobraaten & H. G. Bedigian: Mutant mouse resources. In: Pathology of genetically engineered mice. Eds.: J. M. Ward, J. F. Mahler, R. R. Maronpot, J. P. Sundberg and R. M. Frederickson. Iowa State University Press, Ames, IA, 2000, pp. 3-9.
44. Shastry, B. S.: Gene disruption in mice: Models of development and disease. Mol. Cell. Biochem. 1998, 181, 163-179.
45. Simpson, E. M., C. C. Linder, E. E. Sargent, M. T. Davisson, L. E. Mobraaten & J. J. Sharp: Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Gen. 1997, 16, 19-27.
46. Storer, R. D., J. E. French, J. Haseman, G. Hajian, E. K. LeGrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz & K. A. Soper: p53 +/- hemizygous knockout mouse: Overview of available data. Toxicol. Pathol. 2001, 29 (Suppl.), 30-50.
47. Suarez, H. G.: Activated oncogenes in human tumors. Anticancer Res. 1989, 9, 1331-1343.
48. Suzuki, T., M. Hayashi & T. Sofuni: Initial experiences and future directions for transgenic mouse mutation assays. Mut. Res. 1994, 307, 489-494.
49. Tamaoki, N.: The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol. 2001, 29 (Suppl.), 81-89.
50. Tennant, R. W., J. E. French & J. W. Spalding: Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Env. Health Perspect. 1995, 103, 942-950.
51. Tennant, R. W., S. Stasiewicz, W. C. Eastin, J. H. Mennear & J. W. Spalding: The Tg.Ac (v-Ha-ras) transgenic mouse: nature of the model. Toxicol. Pathol. 2001, 29 (Suppl.), 51-59.
52. Usui, T., M. Mutai, S. Hisada, M. Takoaka, K. A. Soper, B. McCullough & C. Alden: CB6F1-rasH2 mouse: Overview of available data. Toxicol. Pathol. 2001, 29 (Suppl.), 90-108.
53. Valentine, J. L., S. S. Lee, M. J. Seaton, B. Asgharian, G. Farris, J. C. Corton, F. J. Gonzalez & M. A. Medinsky: Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 1996, 141, 205-213.
54. +/- knockout mice: Overview of available data. Toxicol. Pathol. 2001, 29 (Suppl.), 117-127.
55. Van Sloun, P. P., S. W. Wijnhoven, H. J. Kool, R. Slater, G. Weeda, A. A. van Zeeland, P. H. Lohman & H. Vrieling: Determination of spontaneous loss of heterozygosity mutations in Aprt heterozygous mice. Nucleic Acids Res. 1998, 26, 4888-4894.
56. van Steeg, H., A. de Vries, C. T. van Oostrom, J. van Benthem, R. B. Beems & C. F. van Kreijl: DNA repair-deficient Xpa and Xpa/ p53+/- knock-out mice: nature of the models. Toxicol. Pathol. 2001, 29 (Suppl), 109-116.
57. Vassar, R. & M. Citron: Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron 2000, 27, 419-422.
58. Walker, V. E., J. L. Andrews, P. B. Upton, T. R. Skopek, J. G. deBoer, D. M. Walker, X. Shi, H. E. Sussman & N. J. Gorelick: Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice. Environ. Mol. Mutagen. 1999, 34, 167-181.
59. Waters, M., G. Doorman, P. Bushel, M. Cunningham, R. Irwin, A. Merrick, K. Olden, R. Paules, J. Selkirk, S. Stasiewicz, B. Weis, B. Van Houten, N. Walker & R. Tennant: Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. Env. Health Perspect. Toxicogen. 2003, 111, 15-28.
60. Weaver, J. L., J. F. Contrera, B. A. Rosenzweig, K. L. Thompson, P. J. Faustino, J. M. Strong, C. D. Ellison, L. W. Anderson, H. R. Prasanna, P. E. Long-Bradley, K. K. Lin, J. Zhang & F. D. Sistare: An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol. 1998, 26, 532-540.
61. Wei, L.-N.: Transgenic animals as new approaches in pharmacological studies. Ann. Rev. Pharmacol. Toxicol. 1997, 37, 119-141.
62. Wijnhoven, S. W., P. P. Van Sloun, H. J. Kool, G. Weeda, R. Slater, P. H. Lohman, A. A. van Zeeland & H. Vrieling: Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse. Proc. Nat. Acad. Sci. USA 1998, 95, 13759-13764.
63. Wijnhoven, S. W. & H. van Steeg: Transgenic and knockout mice for DNA repair functions in carcinogenesis and mutagenesis. Toxicology 2003, 193, 171-187.
64. Wolf, C. R. & C. J. Henderson: Use of trangenic animals in understanding molecular mechanisms of toxicity. J. Pharm. Pharmacol. 1998, 50, 567-574.
65. Xie, W., J. L. Barwick, M. Dowries, B. Blumberg, C. M. Simon, M. C. Nelson, B. A. Neuschwander-Tetri, E. M. Brunt, P. S. Guzelian & R. M. Evans: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406, 435-439.
66. Zambrowicz, B. P. & A. T. Sands: Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug Discovery 2003, 2, 38-51.
67. Zhang, X. B., C. Urlando, K. S. Tao & J. A. Heddle: Factors affecting somatic mutation frequencies in vivo. Mut. Res. 1995, 338, 189-201.